Literature DB >> 26613899

Erratum to: Iron metabolism and iron supplementation in cancer patients.

Heinz Ludwig1, Rayko Evstatiev2, Gabriela Kornek3, Matti Aapro4, Thomas Bauernhofer5, Veronika Buxhofer-Ausch6, Michael Fridrik7, Dietmar Geissler8, Klaus Geissler9, Heinz Gisslinger3, Elisabeth Koller10, Gerhard Kopetzky11, Alois Lang12, Holger Rumpold13, Michael Steurer14, Houman Kamali15, Hartmut Link16.   

Abstract

Entities:  

Year:  2015        PMID： 26613899      PMCID： PMC4713978          DOI： 10.1007/s00508-015-0893-5

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
Erratum to: WKW (2015) DOI 10.1007/s00508-015-0842-3 In Fig. 2 of the published article the spelling of “Ferroportin” is several times wrong. The correct figure reads:
Fig. 2

Hepcidin—central regulator of iron uptake and release (with kind permission of Evstatiev R, Gasche Ch, and “Gut”)

Hepcidin—central regulator of iron uptake and release (with kind permission of Evstatiev R, Gasche Ch, and “Gut”) We apologise for this error.
  2 in total

1.  Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221).

Authors:  Christine B Ambrosone; Gary R Zirpoli; Alan D Hutson; William E McCann; Susan E McCann; William E Barlow; Kara M Kelly; Rikki Cannioto; Lara E Sucheston-Campbell; Dawn L Hershman; Joseph M Unger; Halle C F Moore; James A Stewart; Claudine Isaacs; Timothy J Hobday; Muhammad Salim; Gabriel N Hortobagyi; Julie R Gralow; George T Budd; Kathy S Albain
Journal:  J Clin Oncol       Date:  2019-12-19       Impact factor: 44.544

2.  Iron Supplementation Effects on Redox Status following Aseptic Skeletal Muscle Trauma in Adults and Children.

Authors:  Chariklia K Deli; Ioannis G Fatouros; Vassilis Paschalis; Athanasios Tsiokanos; Kalliopi Georgakouli; Athanasios Zalavras; Alexandra Avloniti; Yiannis Koutedakis; Athanasios Z Jamurtas
Journal:  Oxid Med Cell Longev       Date:  2017-01-22       Impact factor: 6.543
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.